Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149871 (
deep vein thrombosis
)
12,364
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Venous thromboembolic (VTE) disease, consisting of
deep venous thrombosis
(
DVT
) and pulmonary embolism (PE) is a leading cause of morbidity and mortality. Current prophylactic measures are insufficient to prevent all occurrence in part due to an incomplete understanding of the underlying pathophysiology. Mounting evidence describes interplay between activation of the innate immune system and thrombus development. Recent work has demonstrated that platelet release of
HMGB1
leads to increased microvascular complications following injury. Additionally, platelet
HMGB1
was found to enhance
DVT
and increase the formation of neutrophil extracellular traps (NETs), although the role of
HMGB1
induced NET release in thrombosis remains unexplored. Utilizing a transgenic mouse lacking
HMGB1
specifically from platelets and megakaryocytes we now demonstrate the specific role of platelet-derived
HMGB1
in acute and subacute/chronic venous thrombosis. Platelets account for the majority of circulating
HMGB1
and
HMGB1
deposition within the developing clot. The pro-thrombotic effect of platelet-derived
HMGB1
is mediated through enhanced neutrophil recruitment, NET formation and specifically release of extracellular DNA during NET formation. Taken together, these data suggest that platelet
HMGB1
mediated NET release is a primary regulator of
DVT
formation in mice.
...
PMID:Deep vein thrombosis in mice is regulated by platelet HMGB1 through release of neutrophil-extracellular traps and DNA. 2939 42